A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses

• DOI: 10.1038/s41467-021-26499-y
• Publication Date: 2021-10-27T10:03:47Z
• Authors: Weina Sun; Yonghong Liu; Fatima Amanat; Irene González-Do...; Stephen McCroskery; Stefan Slamanig; Lynda Coughlan; Victoria Rosado; Nicholas Lemus; Sonia Jangra; Raveen Rathnasinghe; Michael Schotsaert; Jose L. Martinez; Kaori Sano; Ignacio Mena; Bruce L. Innis; Ponthip Wirachwong; Duong Huu Thai; Ricardo Das Neves...; Rami Scharf; Richard Hjorth; Rama Raghunandan; Florian Krammer; Adolfo García-Sastre; Peter Palese
• Keywords: Newcastle Disease; spike protein; Sars virus; 2019-20 coronavirus outbreak

Rapid development of COVID-19 vaccines has helped mitigating SARS-CoV-2 spread, but more equitable allocation is necessary to limit the global impact pandemic and emergence additional variants concern. We have developed a vaccine candidate based on Newcastle disease virus (NDV) that can be manufactured at high yields in embryonated eggs. Here, we show NDV vector expressing an optimized spike antigen (NDV-HXP-S) versatile inducing protective antibody responses. NDV-HXP-S administered intramuscularly as inactivated or intranasally live vaccine. GMP-produced Vietnam, Thailand Brazil effective hamster model. Furthermore, intramuscular vaccination with reduces replication tested concerns mice. The immunity conferred by effectively counteracts infection mice hamsters.